Our Pricing

Is Ozempic Wegovy? Private Prescription Access UK

Many UK patients ask is Ozempic Wegovy when researching weight loss treatments online. Whilst both medications contain the same active ingredient—semaglutide—they are distinct products licensed for different purposes by the MHRA. At Cured Pharmacy, our UK-registered clinical team helps patients understand which semaglutide treatment is clinically appropriate for their weight management goals.

Is Ozempic the Same as Wegovy?

No, Ozempic and Wegovy are not the same medication, despite both containing semaglutide as their active pharmaceutical ingredient. Ozempic is licensed exclusively for type 2 diabetes management in the UK, whilst Wegovy holds a separate MHRA licence specifically for chronic weight management in adults with obesity or overweight with weight-related comorbidities [1].

The critical difference lies in dosing and regulatory approval. Ozempic is available in doses up to 1mg weekly for glycaemic control, whereas Wegovy is formulated for weight loss with a maintenance dose of 2.4mg weekly—more than double the maximum Ozempic dose [1][2]. Using Ozempic off-licence for weight loss without diabetes is not recommended by UK prescribers and may not be covered by clinical governance frameworks.

Prescribing semaglutide for weight loss requires the Wegovy formulation to ensure patients receive the evidence-based dosing regimen studied in clinical trials. At Cured Pharmacy, our prescribers follow MHRA licensing and NICE guidance when assessing suitability for semaglutide weight loss treatment.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural gut hormone involved in appetite regulation and glucose metabolism. By activating GLP-1 receptors in the brain, Wegovy reduces hunger signals, increases satiety after meals, and slows gastric emptying—helping patients consume fewer calories without feeling deprived [2].

In the landmark STEP 1 trial, adults using Wegovy 2.4mg weekly alongside lifestyle intervention achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. More than half of participants lost at least 15% of their starting weight—a threshold associated with significant improvements in cardiovascular and metabolic health markers.

The medication is administered via a once-weekly subcutaneous injection using a pre-filled pen device. Dosing begins at 0.25mg weekly and gradually escalates over 16-20 weeks to the maintenance dose of 2.4mg, minimising gastrointestinal side effects during the titration period [1].

Who Can Use Wegovy in the UK?

Wegovy is licensed for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [1]. UK prescribers assess eligibility through a comprehensive clinical consultation covering medical history, current medications, and contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Wegovy vs Ozempic: Key Differences UK Patients Should Know

Beyond licensing and dosing, several practical differences affect which semaglutide product UK prescribers recommend. Wegovy's higher dose delivers greater weight loss efficacy but may increase the likelihood of gastrointestinal side effects during initial weeks. Ozempic's lower doses are optimised for blood sugar control rather than maximal weight reduction.

Availability is another consideration. Ozempic is widely prescribed through NHS diabetes services, whilst Wegovy is primarily accessed privately in the UK due to limited NHS availability outside specialist weight management programmes. At Cured Pharmacy, Wegovy is available from £79.00 following a free online consultation with a UK prescriber, with transparent pricing displayed before assessment.

Insurance and reimbursement also differ. Private health insurance policies may cover Ozempic for diabetes but exclude Wegovy for weight management, as obesity treatment is often classified separately. Patients should verify coverage with their provider before starting treatment.

Can I Switch from Ozempic to Wegovy?

Patients currently using Ozempic for diabetes who wish to pursue weight loss may discuss transitioning to Wegovy with their prescriber. The switch requires clinical review to ensure the higher Wegovy dose is appropriate and to adjust diabetes management if blood sugar control changes with greater weight loss. Your prescriber will create a tailored transition plan to maintain safety and efficacy throughout the changeover period.

Alternative Weight Loss Treatments at Cured Pharmacy

Whilst Wegovy represents the most studied semaglutide formulation for weight loss, other GLP-1 receptor agonists and weight management medications are available through Cured Pharmacy. Saxenda (liraglutide) offers a daily injection option for patients who prefer more frequent dosing or have contraindications to semaglutide. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that demonstrated even greater weight loss in head-to-head trials, though at a different price point [3].

Oral medications such as Orlistat and Mysimba provide non-injectable alternatives for patients uncomfortable with weekly injections. Orlistat works by blocking fat absorption in the gut, whilst Mysimba combines naltrexone and bupropion to reduce cravings and emotional eating. Each treatment carries distinct side effect profiles and efficacy data that UK prescribers consider during consultation.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team assess which treatment aligns with your medical history, weight loss goals, lifestyle preferences, and budget. All prescription medications require online clinical assessment, completed in under three minutes through our secure platform.

How to Access Wegovy Privately in the UK

Accessing Wegovy through Cured Pharmacy begins with a free online consultation completed from your smartphone, tablet, or computer. The clinical questionnaire covers your weight history, previous weight loss attempts, current medications, and relevant medical conditions. A UK-registered prescriber reviews your submission within hours, and if clinically appropriate, issues a private prescription dispensed by our GPhC-registered pharmacy (9012511).

Pricing is transparent before you begin the consultation—Wegovy starts from £79.00 depending on the prescribed dose. There are no hidden consultation fees or membership charges. Your medication is dispatched in 100% discreet packaging with next-day delivery options available across the UK.

Follow-up support is included in your treatment plan. Our clinical team monitors your progress through regular check-ins, adjusts dosing as needed, and provides guidance on managing side effects or optimising lifestyle changes alongside medication. You can contact our pharmacist team on (+44) 116 4646009 during business hours for any questions about your treatment.

What to Expect During Your Consultation

The online assessment asks detailed questions about your BMI, weight-related health conditions, previous medication use, and any contraindications to GLP-1 therapy. Be prepared to provide accurate height and weight measurements, as these determine clinical eligibility. Your prescriber may request additional information or suggest alternative treatments if Wegovy is not suitable based on your medical profile. The entire process typically completes within 24 hours from submission to dispatch.

Managing Side Effects and Maximising Results

The most common side effects of Wegovy are gastrointestinal—nausea, diarrhoea, constipation, and abdominal discomfort—particularly during the dose escalation phase [2]. These symptoms typically diminish as your body adjusts to each new dose level. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can help minimise discomfort.

Serious but rare side effects include pancreatitis, gallbladder disease, and hypoglycaemia (especially in patients taking other diabetes medications). Contact your prescriber immediately if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. Regular monitoring through follow-up consultations helps identify potential complications early.

Wegovy works best when combined with a reduced-calorie diet and increased physical activity. Clinical trials demonstrating 15% average weight loss included structured lifestyle interventions alongside medication [2]. Our clinical team provides evidence-based guidance on sustainable dietary changes and exercise programmes tailored to your fitness level and schedule. Weight loss medications are tools to support behaviour change, not replacements for healthy habits.

Long-Term Use and Maintenance

Wegovy is intended for chronic weight management, meaning long-term use is often necessary to maintain weight loss. Studies show that discontinuing semaglutide typically results in weight regain, as the medication's appetite-suppressing effects cease [4]. Your prescriber will regularly review whether continuing treatment remains clinically beneficial based on your weight loss progress, side effect tolerance, and overall health improvements. Some patients transition to maintenance doses or alternative therapies after achieving their target weight.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.